19230 Federal Register / Vol. 74, No. 80 / Tuesday, April 28, 2009 / Notices 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Center for Complementary & 

Alternative Medicine; Notice of Closed 

Meeting 

Pursuant to Section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the National Advisory 

Council for Complementary and 

Alternative Medicine (NACCAM) 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications 

and/or contract proposals and the 

discussion could disclose confidential 

trade secrets or commercial property 

such as patentable material, and 

personal information concerning 

individuals associated with the grant 

applications and/or contract proposals, 

the disclosure of which would 

constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Advisory 

Council for Complementary and Alternative 

Medicine. 

Date: May 5, 2009. 

Closed: 1 p.m. to 3 p.m. 

Agenda: To review and evaluate grant 

applications and/or proposals. 

Place: National Institutes of Health, 6707 

Democracy Blvd., Suite 401, Bethesda, MD 

20892 (Teleconference). 

Contact Person: Martin H. Goldrosen, PhD, 

Executive Secretary, Director, Division of 

Extramural Activities, National Center for 

Complementary and Alternative Medicine, 

National Institutes of Health, 6707 

Democracy Blvd., Suite 401, Bethesda, MD 

20892, (301) 594–2014. 

This notice is being published less than 15 

days prior to the meeting due to scheduling 

conflicts. 

Dated: April 22, 2009. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. E9–9681 Filed 4–27–09; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Neurological 

Disorders and Stroke; Notice of 

Meeting 

Pursuant to section 10(a) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of a meeting of the 

National Advisory Neurological 

Disorders and Stroke Council. 

The meeting will be open to the 

public, with attendance limited to space 

available. Individuals who plan to 

attend and need special assistance, such 

as sign language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. 

Name of Committee: National Advisory 

Neurological Disorders and Stroke Council; 

Basic and Preclinical Programs 

Subcommittee. 

Date: May 28, 2009. 

Time: 8 a.m. to 10 a.m. 

Agenda: To discuss basic and preclinical 

programs policy. 

Place: National Institutes of Health, 

Building 31, 31 Center Drive, Conference 

Room 7, Bethesda, MD 20892. 

Contact Person: Jill E. Heemskerk, PhD, 

Acting Chief, Technology Development, 

National Institute of Neurological Disorders 

and Stroke, National Institutes of Health, 

6001 Executive Boulevard, Suite 2229, MSC 

9527, Bethesda, MD 20892–9527, (301) 496– 

1779, jh440o@nih.gov. 

In the interest of security, NIH has 

instituted stringent procedures for entrance 

onto the NIH campus. All visitor vehicles, 

including taxicabs, hotel, and airport shuttles 

will be inspected before being allowed on 

campus. Visitors will be asked to show one 

form of identification (for example, a 

government-issued photo ID, driver’s license, 

or passport) and to state the purpose of their 

visit. 

Information is also available on the 

Institute’s/Center’s home page: http:// 

www.ninds.nih.gov, where an agenda and 

any additional information for the meeting 

will be posted when available. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.853, Clinical Research 

Related to Neurological Disorders; 93.854, 

Biological Basis Research in the 

Neurosciences, National Institutes of Health, 

HHS) 

Dated: April 21, 2009. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. E9–9670 Filed 4–27–09; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2009–N–0664] 

Anesthesiology and Respiratory 

Therapy Devices Panel of the Medical 

Devices Advisory Committee; Notice of 

Meeting 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

This notice announces a forthcoming 

meeting of a public advisory committee 

of the Food and Drug Administration 

(FDA). The meeting will be open to the 

public. 

Name of Committee: Anesthesiology and 

Respiratory Therapy Devices Panel of the 

Medical Devices Advisory Committee. 

General Function of the Committee: To 

provide advice and recommendations to the 

agency on FDA’s regulatory issues. 

Date and Time: The meeting will be held 

on May 28, 2009, from 8 a.m. to 5 p.m. 

Location: Holiday Inn, Ballroom, Two 

Montgomery Village Ave., Gaithersburg, MD. 

Contact Person: Neel J. Patel, Center for 

Devices and Radiological Health (HFZ–480), 

Food and Drug Administration, 9200 

Corporate Blvd., 240–276–3700, or FDA 

Advisory Committee Information Line, 1– 

800–741–8138 (301–443–0572 in the 

Washington, DC area), code 3014512624. 

Please call the Information Line for up-todate information on this meeting. A notice in 

the Federal Register about last minute 

modifications that impact a previously 

announced advisory committee meeting 

cannot always be published quickly enough 

to provide timely notice. Therefore, you 

should always check the agency’s Web site 

and call the appropriate advisory committee 

hot line/phone line to learn about possible 

modifications before coming to the meeting. 

Agenda: The committee will discuss, make 

recommendations, and vote on a premarket 

approval application for the SEDASYSTM

Computer-Assisted Personalized Sedation 

System sponsored by Ethicon Endo-Surgery, 

Inc. The device is indicated for the 

intravenous administration of 1% (10 

milligrams/milliliters) propofol injectable 

emulsion for the initiation and maintenance 

of minimal to moderate sedation, as 

identified by the American Society of 

Anesthesiologists Continuum of Depth of 

Sedation, in adult patients (American Society 

of Anesthesiology physical status I, II, or III) 

undergoing colonoscopy and 

esophagogastroduodenoscopy procedures. 

FDA intends to make background material 

available to the public no later than 2 

business days before the meeting. If FDA is 

unable to post the background material on its 

Web site prior to the meeting, the background 

material will be made publicly available at 

the location of the advisory committee 

meeting, and the background material will be 

posted on FDA’s Web site after the meeting. 

Background material is available at http:// 

www.fda.gov/ohrms/dockets/ac/acmenu.htm, 

click on the year 2009 and scroll down to the 

appropriate advisory committee link. 

Procedure: Interested persons may present 

data, information, or views, orally or in 

writing, on issues pending before the 

committee. Written submissions may be 

made to the contact person on or before May 

15, 2009. Oral presentations from the public 

will be scheduled for approximately 30 

minutes at the beginning of the committee 

deliberations and for approximately 30 

minutes near the end of committee 

deliberations. Those desiring to make formal 

oral presentations should notify the contact 

person and submit a brief statement of the 


erowe on PROD1PC64 with NOTICES
Federal Register / Vol. 74, No. 80 / Tuesday, April 28, 2009 / Notices 19231 

general nature of the evidence or arguments 

they wish to present, the names and 

addresses of proposed participants, and an 

indication of the approximate time requested 

to make their presentation on or before May 

6, 2009. Time allotted for each presentation 

may be limited. If the number of registrants 

requesting to speak is greater than can be 

reasonably accommodated during the 

scheduled open public hearing session, FDA 

may conduct a lottery to determine the 

speakers for the scheduled open public 

hearing session. The contact person will 

notify interested persons regarding their 

request to speak by May 7, 2009. 

Persons attending FDA’s advisory 

committee meetings are advised that the 

agency is not responsible for providing 

access to electrical outlets. 

FDA welcomes the attendance of the 

public at its advisory committee meetings 

and will make every effort to accommodate 

persons with physical disabilities or special 

needs. If you require special accommodations 

due to a disability, please contact AnnMarie 

Williams, Conference Management Staff, at 

240–276–8932, at least 7 days in advance of 

the meeting. 

FDA is committed to the orderly conduct 

of its advisory committee meetings. Please 

visit our Web site at http://www.fda.gov/oc/ 

advisory/default.htm for procedures on 

public conduct during advisory committee 

meetings. 

Notice of this meeting is given under the 

Federal Advisory Committee Act (5 U.S.C. 

app. 2). 

Dated: April 22, 2009. 

Randall W. Lutter, 

Deputy Commissioner for Policy. 

[FR Doc. E9–9642 Filed 4–27–09; 8:45 am] 

BILLING CODE 4160–01–S 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2009–N–0664] 

Science Board to the Food and Drug 

Administration; Notice of Meeting 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

This notice announces a forthcoming 

meeting of a public advisory committee 

of the Food and Drug Administration 

(FDA). The meeting will be open to the 

public. 

Name of Committee: Science Board to the 

Food and Drug Administration (Science 

Board). 

General Function of the Committee: The 

Science Board provides advice primarily to 

the Commissioner of Food and Drugs and 

other appropriate officials on specific 

complex and technical issues, as well as 

emerging issues within the scientific 

community in industry and academia. 

Additionally, the Science Board provides 

advice to the agency on keeping pace with 

technical and scientific evolutions in the 

fields of regulatory science, on formulating 

an appropriate research agenda, and on 

upgrading its scientific and research facilities 

to keep pace with these changes. It will also 

provide the means for critical review of 

agency sponsored intramural and extramural 

scientific research programs. 

Date and Time: The meeting will be held 

on Monday, May 18, 2009, from 9 a.m. to 3 

p.m. 

Addresses: Hilton Washington DC/ 

Rockville Hilton, 1750 Rockville Pike, 

Rockville, MD 20852. 

Contact Person: Carlos Pen ̃ a, Office of the 

Commissioner, Food and Drug 

Administration (HF–33), 5600 Fishers Lane, 

Rockville, MD 20857, 301–827–6687, or FDA 

Advisory Committee Information Line, 1– 

800–741–8138 (301–443–0572 in the 

Washington, DC area), code 3014512603. 

Please call the Information Line for up-todate information on this meeting. A notice in 

the Federal Register about last minute 

modifications that impact a previously 

announced advisory committee meeting 

cannot always be published quickly enough 

to provide timely notice. Therefore, you 

should always check the agency’s Web site 

and call the appropriate advisory committee 

hot line/phone line to learn about possible 

modifications before coming to the meeting. 

Agenda: The Science Board will hear about 

and discuss updates from the following 

subcommittees: (1) The review of each 

Center’s projects within scientific priority 

areas, (2) the review of research at the Center 

for Veterinary Medicine, and (3) the review 

of FDA’s scientific information technology 

infrastructure modernization initiatives. The 

Science Board will also hear updates on 

rapid detection of Salmonella in foods and 

the handling of biospecimens used for 

genomic and proteomic analyses. 

FDA intends to make background material 

available to the public no later than 2 

business days before the meeting. If FDA is 

unable to post the background material on its 

Web site prior to the meeting, the background 

material will be made publicly available at 

the location of the advisory committee 

meeting, and the background material will be 

posted on FDA’s Web site after the meeting. 

Background material is available at http:// 

www.fda.gov/ohrms/dockets/ac/acmenu.htm, 

click on the year 2009 and scroll down to the 

appropriate advisory committee link. 

Procedure: Interested persons may present 

data, information, or views, orally or in 

writing, on issues pending before the 

committee. Written submissions may be 

made to the contact person on or before May 

11, 2009. Oral presentations from the public 

will be scheduled between approximately 1 

p.m. and 2 p.m. Those desiring to make 

formal oral presentations should notify the 

contact person and submit a brief statement 

of the general nature of the evidence or 

arguments they wish to present, the names 

and addresses of proposed participants, and 

an indication of the approximate time 

requested to make their presentation on or 

before May 7, 2009. Time allotted for each 

presentation may be limited. If the number of 

registrants requesting to speak is greater than 

can be reasonably accommodated during the 

scheduled open public hearing session, FDA 

may conduct a lottery to determine the 

speakers for the scheduled open public 

hearing session. The contact person will 

notify interested persons regarding their 

request to speak by May 8, 2009. 

Persons attending FDA’s advisory 

committee meetings are advised that the 

agency is not responsible for providing 

access to electrical outlets. 

FDA welcomes the attendance of the 

public at its advisory committee meetings 

and will make every effort to accommodate 

persons with physical disabilities or special 

needs. If you require special accommodations 

due to a disability, please contact Dr. Carlos 

Pen ̃ a at least 7 days in advance of the 

meeting. 

FDA is committed to the orderly conduct 

of its advisory committee meetings. Please 

visit our Web site at http://www.fda.gov/oc/ 

advisory/default.htm for procedures on 

public conduct during advisory committee 

meetings. 

Notice of this meeting is given under the 

Federal Advisory Committee Act (5 U.S.C. 

app. 2). 

Dated: April 22, 2009. 

Randall W. Lutter, 

Deputy Commissioner for Policy. 

[FR Doc. E9–9643 Filed 4–27–09; 8:45 am] 

BILLING CODE 4160–01–S 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2009–N–0664] 

Neurological Devices Panel of the 

Medical Devices Advisory Committee; 

Notice of Meeting 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

This notice announces a forthcoming 

meeting of a public advisory committee 

of the Food and Drug Administration 

(FDA). The meeting will be open to the 

public. 

Name of Committee: Neurological Devices 

Panel of the Medical Devices Advisory 

Committee. 

General Function of the Committee: To 

provide advice and recommendations to the 

agency on FDA’s regulatory issues. 

Date and Time: The meeting will be held 

on May 14, 2009, from 8 a.m. to 5 p.m. 

Location: Holiday Inn, Ballroom, Two 

Montgomery Village Ave., Gaithersburg, MD. 

Contact Person: Peter L. Hudson, Center for 

Devices and Radiological Health, (HFZ–410), 

Food and Drug Administration, 9200 

Corporate Blvd., Rockville, MD 20850, 240– 

276–3737, or FDA Advisory Committee 

Information Line, 1–800–741–8138 (301– 

443–0572 in the Washington, DC area), code 

3014512513. Please call the Information Line 

for up-to-date information on this meeting. A 


erowe on PROD1PC64 with NOTICES